SCHEMBL21150841

SCHEMBL21150841

C#Cc1cnc(N2CC(C(=O)OC)C2)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
ACACB O00763 8/20 0.39
NAMPT P43490 1/20 0.37
BRD4 O60885 1/20 0.36
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HDAC9 Q9UKV0 1/20 0.35
HDAC5 Q9UQL6 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20474703 0.82 ACACB (0.47) KDM4EACACBNAMPTBRD4ALDH1A1
SCHEMBL21151895 0.81 KDM4E (0.42) KDM4EACACBALDH1A1HPGDHDAC3
SCHEMBL3585722 0.80 KDM4E (0.50) KDM4EALDH1A1GAAHPGDMEN1
SCHEMBL16433994 0.78 ACACB (0.50) ACACBHDAC3HDAC4HDAC1HDAC7
SCHEMBL26089025 0.75 CHRM3 (0.41)
SCHEMBL23744152 0.72 PTPN11 (0.43) ACACBHDAC1
SCHEMBL3664698 0.70 KDM4E (0.50) KDM4EACACBALDH1A1GAAHPGD
SCHEMBL20456782 0.69 CHRNB2 (0.43)
SCHEMBL18255043 0.69 KDM4E (0.58) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL20552789 0.68 POLB (0.59) KDM4EALDH1A1HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572370-B2 CD16A binding agents and uses thereof BIOHAVEN THERAPEUTICS LTD. (US) 2023-02-07 US disclosed
WO-2019136442-A1 CD16A BINDING AGENTS AND USES THEREOF KLEO PHARMACEUTICALS, INC. (US) 2019-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572370-B2 CD16A binding agents and uses thereof FCGR1A, FCGR2A, FCGR3B KDM4E 2126/4885ACACB 4671/4885NAMPT 1356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.